139 patents currently held
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
76 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
73
Ending by 2030
Dec 2026
Next term end
76
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2028 · High confidence
Also notable
Ends Dec 2026 · High confidence
Also notable
Ends May 2029 · Medium confidence
Chemically Modified Small Molecules
US 7,786,133
The most cited patent in this portfolio, cited by 122 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2028.
Multi-Arm Polymer Prodrugs
US 7,744,861
Cited by 119 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2026.
Oligomer-Opioid Agonist Conjugates
US 8,173,666
Cited by 52 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Formerly held, still cited
Notable
Ends Oct 2032 · High confidence
Cited by 116 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
now held by Stamford Devices Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 13 to 18, 2026 · next Dec 13
- 4 fees due Jan 21 to 28, 2027 · next Jan 21
- 6 fees due Feb 4 to 18, 2027 · next Feb 4
- 2 fees due Mar 5 to 10, 2027 · next Mar 5
- 1 fee due Apr 8, 2027The maintenance fee for Oligomer-Containing Benzamide-Based Compounds (US 10,434,181) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 5 fees due May 3 to 26, 2027 · next May 3
- 3 fees due Jun 1 to 24, 2027 · next Jun 1
- 10 fees due Jul 5 to 12, 2027 · next Jul 5
- 1 fee due Aug 23, 2027The maintenance fee for Oligomer-Containing Substituted Aromatic Triazine Compounds (US 9,266,845) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Method of Making Releasable Polymeric Reagents (US 11,932,726) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Acid Salt Forms of Polymer-Drug Conjugates and Alkoxylation Methods (US 9,320,808) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
Recent changes
- 6 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 76 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Oligomer-Opioid Agonist Conjugates | 14 in force | to May 2029 |
| Polymeric Alpha-Hydroxy Aldehyde and Ketone Reagents and Conjugation Method | 5 in force | to Sep 2029 |
| Conjugates of an IL-2 Moiety and a Polymer | 4 in force | to Apr 2032 |
| Oligomer-Containing Substituted Aromatic Triazine Compounds | 4 in force | to Jan 2031 |
| Kappa Opioid Agonists and Uses Thereof | 3 in force | to Jun 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,744,861 | Multi-Arm Polymer Prodrugs In force · High confidence | In force | High confidence | |
| US 7,608,663 | Method of Preparing Propionic Acid-Terminated Polymers In force · High confidence | In force | High confidence | |
| US 10,232,042 | Conjugates of an Anti-Tnf-Alpha Antibody In force · Medium confidence | In force | Medium confidence | |
| US 9,636,412 | Conjugates of an Anti-Tnf-Alpha Antibody In force · High confidence | In force | High confidence | |
| US 7,872,082 | Method for Preparing Polymer Maleimides In force · High confidence | In force | High confidence | |
| US 8,937,180 | Method for Preparing a Polymer Conjugate In force · Medium confidence | In force | Medium confidence | |
| US 7,887,789 | Polymer Derivatives Having Particular Atom Arrangements In force · High confidence | In force | High confidence | |
| US 8,440,687 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 8,569,343 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 8,575,196 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 139: 13 patents in force now held by others · 291 patents ended · 7 applications pending · 170 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.